PATENT CLAIM ANALYSIS

Application Number: 15768025
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "210210"]

Abstract:
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

Claim (Index 53):
Compounds for the use according to  claim 51 , wherein the co-administration of the combination therapy is carried out in a free dose combination therapy by co-administration of the compounds as defined in any of the preceding claims and the at least one additional pharmaceutically active compound in free doses of the respective compounds, either by simultaneous administration of the individual compounds or by sequential use of the individual compounds distributed over a time period.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.25532
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15769148', '14310254', '15517528', '14007533', '15185186']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7910105942060194
- 35 USC 102 Novelty (BERT): 0.5482643018846919
- Combined Prediction Score: 0.7667359649738866
- Mean Citation Score: 298.633386
- Max Citation Score: 422.5474
- Similarity Product: 272.2974531391144

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test